BSPM - Biostar Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.4355
-0.1645 (-27.42%)
As of 9:31AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.6000
Open0.4655
Bid0.0000 x 1400
Ask0.0000 x 800
Day's Range0.4355 - 0.4655
52 Week Range0.2800 - 5.9700
Volume513
Avg. Volume14,752
Market Cap1.148M
Beta (3Y Monthly)3.14
PE Ratio (TTM)1.28
EPS (TTM)0.3400
Earnings DateApr 11, 2018 - Apr 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • ACCESSWIRE5 months ago

    Today's Research Reports on Stocks to Watch: Biostar Pharmaceuticals and ABIOMED

    NEW YORK, NY / ACCESSWIRE / July 27, 2018 / Biostar shares saw a rebound on Thursday, closing the day up over 27% after falling on Wednesday when Wall Street learned the company had received a delisting ...

  • ACCESSWIRE5 months ago

    Biostar Pharmaceuticals Received Nasdaq Delisting Notification

    XIANYANG, CHINA / ACCESSWIRE / July 25, 2018 / Biostar Pharmaceuticals, Inc. (BSPM) (''the Company''), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on July 19, 2018 it received a notification letter from Nasdaq Listing Qualifications (''Nasdaq'') advising the Company that following review of the Company's plan of compliance, the Nasdaq staff determined to delist the Company's common stock from the Nasdaq Capital Market. The delisting notification stated that such delisting would be effective at the opening of business on July 30, 2018 unless the Company requests an appeal of the delisting determination. As previously disclosed, the Company was cited for failures to comply with this Listing Rule because it had not filed its Form 10-K for the year ended December 31, 2017 and its Form 10-Q for the period ended March 31, 2018.

  • How Does Biostar Pharmaceuticals Inc (NASDAQ:BSPM) Affect Your Portfolio Returns?
    Simply Wall St.6 months ago

    How Does Biostar Pharmaceuticals Inc (NASDAQ:BSPM) Affect Your Portfolio Returns?

    If you are a shareholder in Biostar Pharmaceuticals Inc’s (NASDAQ:BSPM), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • ACCESSWIRE7 months ago

    Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice

    XIANYANG, CHINA / ACCESSWIRE / May 30, 2018 / Biostar Pharmaceuticals, Inc. (BSPM) ("the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on May 23, 2018 it received a notification letter from Nasdaq Listing Qualifications ("Nasdaq") advising the Company that, since it had not filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2018, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) for continued listing. As previously disclosed, on April 19, 2018, the Company received a notification letter from Nasdaq advising the Company that, since it had not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, the Company was not in compliance with Nasdaq Listing Rules.

  • Did Biostar Pharmaceuticals Inc (NASDAQ:BSPM) Create Value For Investors Over The Past Year?
    Simply Wall St.7 months ago

    Did Biostar Pharmaceuticals Inc (NASDAQ:BSPM) Create Value For Investors Over The Past Year?

    Biostar Pharmaceuticals Inc (NASDAQ:BSPM) delivered a less impressive 2.59% ROE over the past year, compared to the 12.26% return generated by its industry. BSPM’s results could indicate a relatively inefficientRead More...

  • Cheap Stocks To Invest In
    Simply Wall St.7 months ago

    Cheap Stocks To Invest In

    Undervalued companies, such as Foot Locker and Biostar Pharmaceuticals, are those that trade at a price below their actual values. Investors can benefit from buying these companies while they areRead More...

  • PR Newswire8 months ago

    Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice

    XIANYANG, China, April 23, 2018 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (BSPM) ("the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on received a notification letter from Nasdaq Listing Qualifications ("Nasdaq") advising the Company that, since it had not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) for continued listing. The Company is required within 60 calendar days of the Nasdaq notification to submit a plan of compliance with the foregoing continued listing deficiency. If the Company's plan is approved by the Nasdaq staff, the Company may be eligible for a listing exception of up to 180 calendar days (or until October 15, 2018) to regain compliance.

  • Who Are The Major Shareholders Of Biostar Pharmaceuticals Inc (NASDAQ:BSPM)?
    Simply Wall St.8 months ago

    Who Are The Major Shareholders Of Biostar Pharmaceuticals Inc (NASDAQ:BSPM)?

    In this article, I’m going to take a look at Biostar Pharmaceuticals Inc’s (NASDAQ:BSPM) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • Best Cheap Stocks To Buy
    Simply Wall St.9 months ago

    Best Cheap Stocks To Buy

    Undervalued companies are those that trade at a price lower than their actual values, such as Park-Ohio Holdings and Nautilus. There’s a few ways you can value a company. TheRead More...

  • Is Biostar Pharmaceuticals Inc (NASDAQ:BSPM) A Financially Sound Company?
    Simply Wall St.9 months ago

    Is Biostar Pharmaceuticals Inc (NASDAQ:BSPM) A Financially Sound Company?

    Biostar Pharmaceuticals Inc (NASDAQ:BSPM) is a small-cap stock with a market capitalization of US$8.94M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...

  • PR Newswire10 months ago

    Biostar Pharmaceuticals, Inc. Announces Plans to Launch a New eCommerce Sales Platform

    XIANYANG, China, Feb. 21, 2018 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its plans to launch a new e-commerce sales platform (the "Sales Platform") following nearly ten months of research and preparation. The Company intends to complete this platform by the end of March 2018 and launch it during the second fiscal quarter of 2018. The Sales Platform will take a full advantage of various IT trends, including the latest trending content, sharing economy, innovative promotion of traditional and new e-commerce, Wechat business distribution system, etc. The Company will also include its B2C online shopping mall within the Sales Platform to promote its product line.

  • Best Undervalued Stock in February
    Simply Wall St.10 months ago

    Best Undervalued Stock in February

    Companies, such as Biostar Pharmaceuticals, are deemed to be undervalued because their shares are currently trading below their true values. Investors can profit from the difference by investing in theseRead More...

  • PR Newswire10 months ago

    Shaanxi Aoxing Pharmaceutical Co., Ltd. Renewed its GMP Certification

    XIANYANG, China, Feb. 7, 2018 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its variable interest entity in China, Shaanxi Aoxing Pharmaceutical Co., Ltd. ("Aoxing"), has renewed its Good Manufacturing Practices (GMP) certificate and Pharmaceutical Production License. The Company received the renewed GMP certificate evidencing compliance on January 31, 2018.

  • ACCESSWIRE10 months ago

    Biostar Pharma Post Huge Gains, Pipeline Review, and a New Product

    NEW YORK, NY / ACCESSWIRE / February 1, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Why Biostar Pharmaceuticals Inc (NASDAQ:BSPM) May Not Be As Efficient As Its Industry
    Simply Wall St.11 months ago

    Why Biostar Pharmaceuticals Inc (NASDAQ:BSPM) May Not Be As Efficient As Its Industry

    Biostar Pharmaceuticals Inc’s (NASDAQ:BSPM) most recent return on equity was a substandard 2.66% relative to its industry performance of 11.58% over the past year. Though BSPM’s recent performance is underwhelming,Read More...

  • December Undervalued Opportunities – Biostar Pharmaceuticals And More
    Simply Wall St.last year

    December Undervalued Opportunities – Biostar Pharmaceuticals And More

    Biostar Pharmaceuticals and Goodrich Petroleum are two of the stocks I have identified as undervalued. This means their current share prices are trading at levels less than what the companiesRead More...